Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Transgenomic Licenses Exclusive Rights to Multiplexed Ice Cold-PCRTM Technology

Published: Wednesday, May 28, 2014
Last Updated: Thursday, May 29, 2014
Bookmark and Share
Multiplexed Version of Revolutionary Technology Enables Efficient Detection of Multiple Cancer Mutations in a Single Liquid Assay

Transgenomic, Inc. announced that it has signed a license with the Dana-Farber Cancer Institute for worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCRTM technology.
 
The new license is exclusive to Transgenomic and expands the current relationship with Dana-Farber. It covers all fields and applications of the multiplexed technology, which makes possible the simultaneous detection of multiple DNA mutations from a single liquid sample, such as blood or urine.
 
Paul Kinnon, President and Chief Executive Officer of Transgenomic commented, “We believe MX ICE COLD-PCR is a critical enabling technology that represents a major leap forward in individualized cancer therapy. For the first time, it will allow comprehensive and affordable tumor genomic profiling without the need for tumor biopsies, a prerequisite if ongoing monitoring and optimization of cancer therapy is to become an everyday reality.”
 
Mr. Kinnon continued, “Multiplexing makes our ICE COLD-PCR technology far more efficient and allows us to assemble targeted panels of relevant mutations that can be simultaneously analyzed from a single sample. This should greatly increase its availability for routine use in cancer therapy, as well as for our biopharmaceutical customers who plan to use MX ICE COLD-PCR to develop new cancer treatments and companion diagnostics.”
 
ICE COLD-PCR selectively focuses on only the mutated DNA in tumors that is useful for cancer diagnosis, monitoring and treatment. It detects mutated DNA at very high sensitivity—initial validation studies show it is 100-400 fold more sensitive than conventional approaches. Uniquely, ICE COLD-PCR also enables identification of all tumor mutations – both those already known to cancer researchers as well as new mutations not detected before.
 
Importantly, the ultra-high sensitivity of ICE COLD-PCR allows DNA testing to be done using easily accessible samples, such as blood, plasma and urine, eliminating the need for tumor biopsies, which are invasive, painful and expensive. By enabling the use of these “liquid biopsies”, ICE COLD-PCR makes it possible to conduct repeated assessments of a cancer patient’s disease status both initially and as treatment proceeds, providing valuable information to help guide treatment decisions.
 
ICE COLD-PCR can also analyze DNA from fine needle aspirates, core-biopsies, or directly from tumors, and it can be used with standard Sanger sequencing, next generation sequencing, digital PCR and other technologies, as research in Dr. Mike Makrigiorgos’ lab at Dana-Farber Cancer Institute has shown.
 
Transgenomic’s current version of the ICE COLD-PCR technology is also exclusively licensed from Dana-Farber.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Transgenomic Awarded NIH Grant
STTR grant supports addition of greater multiplexing capabilities to ICE COLD-PCR, an advanced technology that enables use of tissue or liquid biopsy samples and provides up to 500-fold increase in mutation detection on any sequencing platform.
Monday, January 04, 2016
Transgenomic Licenses Liquid Biopsy Technology to University of Melbourne
Commercial agreement for Australia allows University of Melbourne to use Transgenomic’s multiplexed ICE COLD-PCR™ product for cancer diagnostics and biomarker identification.
Friday, September 18, 2015
Transgenomic, Raptor to Collaborate
Transgenomic to provide genetic profiling for Raptor's clinical trial evaluating drug for the treatment of Leigh Syndrome and other mitochondrial disorders.
Friday, April 04, 2014
Transgenomic Acquires ScoliScore™ AIS Prognostic Test from Axial Biotech
Commercially established, highly accurate test reduces dangerous radiation exposure in adolescents diagnosed with Scoliosis.
Wednesday, August 29, 2012
Transgenomic and The Medical College Of Wisconsin Announce Collaboration
Transgenomic will offer next-generation genetic testing services performed at the MCW Clinical Sequencing Program.
Monday, July 30, 2012
Transgenomic Announces $3 Million Convertible Note Financing
The company announced it has entered into a Convertible Promissory Note Purchase Agreement in the aggregate amount of $3.0 million with entities associated with Third Security, LLC.
Monday, January 09, 2012
Transgenomic, Inc. To Purchase Clinical Data, Inc.'s Diagnostic Business
Transgenomic, Inc. announced today the signing of a definitive agreement for Transgenomic to acquire the diagnostic business of Clinical Data, Inc.
Tuesday, November 30, 2010
Scientific News
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
£14m EU Project To Aid Meningitis Diagnosis and Cut Antibiotic Use
An international team of doctors are aiming to develop a rapid test to allow medics to quickly identify bacterial infection in children.
Bringing AFM to Medical Diagnostics
Company has announced that its NanoWizard® AFM and ForceRobot® systems are being used in the field of medical diagnostics in the Supersensitive Molecular Layer Laboratory of POSTECH in Korea.
Scientific Gains May Make Electronic Nose the Next Everyday Device
UT Dallas team breathes new life into possibilities by using CMOS integrated circuits technology.
Electronic Sensor Tells Dead Bacteria From Live
The sensor, which measures 'osmoregulation', is a potential future tool for medicine and food safety.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
A Future Tool for Medicine, Food Safety
A new type of electronic sensor that might be used to quickly detect and classify bacteria for medical diagnostics and food safety has passed a key hurdle by distinguishing between dead and living bacteria cells.
Genome Sequencing Helps Determine End of TB Outbreak
Using genome sequencing, researchers from the University of British Columbia, along with colleagues at the Imperial College in London, now have the ability to determine when a tuberculosis (TB) outbreak is over.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Shimmer Partners with Harvard's Wyss Institute
Partnership to support ongoing research focused on remote patient monitoring using wearable sensing technology.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!